Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin that simultaneously targets the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) signaling pathways. Dilpacimab has significant potential in cancer research due to its dual targeting of tumor angiogenesis and Notch signaling.
Purity:
95.00%
CAS Number:
[1791420-09-1]
Target:
VEGFR|||Gamma-secretase
* VAT and and shipping costs not included. Errors and price changes excepted
